{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T23:01:21Z","timestamp":1783983681704,"version":"3.55.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T00:00:00Z","timestamp":1705708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.vaccine.2024.01.037","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T15:42:51Z","timestamp":1705938171000},"page":"1094-1107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Background incidence rates of health outcomes in populations at risk for Lyme disease using US administrative claims data"],"prefix":"10.1016","volume":"42","author":[{"given":"Jill","family":"Dreyfus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapna","family":"Munnangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0157-3081","authenticated-orcid":false,"given":"Camilla","family":"Bengtsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9161-5937","authenticated-orcid":false,"given":"B\u00e1rbara","family":"Correia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0688-990X","authenticated-orcid":false,"given":"Rejane","family":"Figueiredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0728-876X","authenticated-orcid":false,"given":"James H.","family":"Stark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Zawora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0607-7880","authenticated-orcid":false,"given":"Mark S.","family":"Riddle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D.","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Ianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Naredo Turrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Svanstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9346-6202","authenticated-orcid":false,"given":"Mitchell","family":"DeKoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.01.037_b0005","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.idc.2015.02.010","article-title":"Epidemiology of lyme disease","volume":"29","author":"Mead","year":"2015","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.vaccine.2024.01.037_b0010","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1089\/vbz.2022.0071","article-title":"Incidence of Lyme Borreliosis in Europe from National Surveillance Systems (2005\u20132020)","volume":"23","author":"Burn","year":"2023","journal-title":"Vector Borne Zoonotic Dis Larchmt N"},{"key":"10.1016\/j.vaccine.2024.01.037_b0015","doi-asserted-by":"crossref","unstructured":"Kugeler KJ, Schwartz AM, Delorey MJ, Mead PS, Hinckley AF. Estimating the Frequency of Lyme Disease Diagnoses, United States, 2010\u20132018 - Volume 27, Number 2\u2014February 2021 - Emerging Infectious Diseases journal - CDC n.d. 10.3201\/eid2702.202731.","DOI":"10.3201\/eid2702.202731"},{"key":"10.1016\/j.vaccine.2024.01.037_b0020","unstructured":"Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Vector-Borne Diseases (DVBD). Lyme Disease Maps: Most Recent Year | Lyme Disease | CDC 2021. https:\/\/www.cdc.gov\/lyme\/datasurveillance\/maps-recent.html (accessed December 16, 2021)."},{"key":"10.1016\/j.vaccine.2024.01.037_b0025","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0140-6736(11)60103-7","article-title":"Lyme borreliosis","volume":"379","author":"Stanek","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.01.037_b0030","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1086\/376914","article-title":"Asymptomatic Infection with Borrelia burgdorferi","volume":"37","author":"Steere","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.01.037_b0035","unstructured":"Pfizer. An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15) (VALOR). ID: NCT05477524. ClinicalTrialsGov n.d. https:\/\/clinicaltrials.gov\/study\/NCT05477524 (accessed June 23, 2023)."},{"key":"10.1016\/j.vaccine.2024.01.037_b0040","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05477524?cond=Lyme+Disease&draw=2&rank=2 n.d."},{"key":"10.1016\/j.vaccine.2024.01.037_b0045","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s40264-020-01031-1","article-title":"Incidence rates of autoimmune diseases in European healthcare databases: a contribution of the ADVANCE project","volume":"44","author":"Willame","year":"2021","journal-title":"Drug Saf"},{"key":"10.1016\/j.vaccine.2024.01.037_b0050","doi-asserted-by":"crossref","first-page":"7205","DOI":"10.1016\/j.vaccine.2012.10.017","article-title":"The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England","volume":"30","author":"van Hoek","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.01.037_b0055","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/pds.3918","article-title":"Pharmacoepidemiological considerations in observed-to-expected analyses for vaccines","volume":"25","author":"Mahaux","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2024.01.037_b0060","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/pds.4419","article-title":"Methodology for computing the burden of disease of adverse events following immunization","volume":"27","author":"McDonald","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2024.01.037_b0065","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(09)61877-8","article-title":"Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines","volume":"374","author":"Black","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.01.037_b0070","doi-asserted-by":"crossref","first-page":"8084","DOI":"10.1016\/j.vaccine.2018.10.052","article-title":"Incidence of outcomes relevant to vaccine safety monitoring in a US commercially-insured population","volume":"36","author":"Esposito","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.01.037_b0075","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1016\/j.vaccine.2021.05.016","article-title":"Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines","volume":"39","author":"Gubernot","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.01.037_b0080","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.vaccine.2022.11.031","article-title":"Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases \u2013 an ACCESS cohort study","volume":"41","author":"Willame","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.01.037_b0085","unstructured":"Department of Public Health: Bureau of Infectious Disease and Laboratory Sciences. Lyme Disease - Fact sheet about Lyme disease. Lyme Dis Massgov n.d. https:\/\/www.mass.gov\/service-details\/lyme-disease (accessed June 15, 2023)."},{"key":"10.1016\/j.vaccine.2024.01.037_b0090","unstructured":"http:\/\/www.encepp.eu\/phact_links.shtml n.d."},{"key":"10.1016\/j.vaccine.2024.01.037_b0095","doi-asserted-by":"crossref","unstructured":"Li X, Ostropolets A, Makadia R, Shaoibi A, Rao G, Sena AG, et al. Characterizing the incidence of adverse events of special interest for COVID-19 vaccines across eight countries: a multinational network cohort study. MedRxiv Prepr Serv Health Sci 2021:2021.03.25.21254315. 10.1101\/2021.03.25.21254315.","DOI":"10.1101\/2021.03.25.21254315"},{"key":"10.1016\/j.vaccine.2024.01.037_b0100","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.3201\/eid1709.101987","article-title":"Geographic distribution of endemic fungal infections among older persons, United States","volume":"17","author":"Baddley","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2024.01.037_b0105","unstructured":"Centers for Disease Control and Prevention. Alpha-gal Syndrome n.d. https:\/\/www.cdc.gov\/ticks\/alpha-gal\/index.html (accessed June 14, 2023)."},{"key":"10.1016\/j.vaccine.2024.01.037_b0110","unstructured":"Centers for Disease Control and Prevention. Lyme carditis n.d. https:\/\/www.cdc.gov\/lyme\/treatment\/lymecarditis.html (accessed June 14, 2023)."},{"key":"10.1016\/j.vaccine.2024.01.037_b0115","unstructured":"Centers for Disease Control and Prevention. Symptoms of Tickborne Illness n.d. https:\/\/www.cdc.gov\/ticks\/symptoms.html (accessed June 14, 2023)."},{"key":"10.1016\/j.vaccine.2024.01.037_b0120","unstructured":"US census. Https:\/\/WwwCensusGov\/Quickfacts\/Fact\/Table\/US\/RHI125221#RHI125221 n.d."},{"key":"10.1016\/j.vaccine.2024.01.037_b0125","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/jrh.12116","article-title":"Rural Healthy people 2020: new decade, same challenges","volume":"31","author":"Bolin","year":"2015","journal-title":"J Rural Health"},{"key":"10.1016\/j.vaccine.2024.01.037_b0130","unstructured":"Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Division of Population Health. BRFSS Prevalence & Trends Data n.d. https:\/\/nccd.cdc.gov\/BRFSSPrevalence\/rdPage.aspx?rdReport=DPH_BRFSS.ExploreByTopic&irbLocationType=StatesAndMMSA&islClass=CLASS08&islTopic=TOPIC24&islYear=2021&rdRnd=10473 (accessed June 14, 2023)."},{"key":"10.1016\/j.vaccine.2024.01.037_b0135","doi-asserted-by":"crossref","first-page":"E494","DOI":"10.1503\/cmaj.160823","article-title":"Regional variations in ambulatory care and incidence of cardiovascular events","volume":"189","author":"Tu","year":"2017","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.vaccine.2024.01.037_b0140","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.ajcnut.2023.02.014","article-title":"Dietary contributions of food outlets by urbanization level in the US population aged 2 years and older-NHANES 2013\u20132018","volume":"117","author":"Ansai","year":"2023","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.vaccine.2024.01.037_b0145","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40537-020-00315-8","article-title":"Preventive healthcare policies in the US: solutions for disease management using Big Data Analytics","volume":"7","author":"Batarseh","year":"2020","journal-title":"J Big Data"},{"key":"10.1016\/j.vaccine.2024.01.037_b0150","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.amjcard.2020.05.011","article-title":"Limitations of randomized clinical trials","volume":"129","author":"Kostis","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.vaccine.2024.01.037_b0155","doi-asserted-by":"crossref","first-page":"e045343","DOI":"10.1136\/bmjopen-2020-045343","article-title":"Impact of COVID-19 pandemic on utilisation of healthcare services: a systematic review","volume":"11","author":"Moynihan","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2024.01.037_b0160","doi-asserted-by":"crossref","first-page":"e212487","DOI":"10.1001\/jamahealthforum.2021.2487","article-title":"Trends in US health insurance coverage during the COVID-19 pandemic","volume":"2","author":"Bundorf","year":"2021","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.vaccine.2024.01.037_b0165","first-page":"839","article-title":"One-Year risk of myocarditis after COVID-19 infection: a systematic review and meta-analysis","volume":"39","author":"Zuin","year":"2023","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.vaccine.2024.01.037_b0170","doi-asserted-by":"crossref","first-page":"e2116420","DOI":"10.1001\/jamanetworkopen.2021.16420","article-title":"Incidence of multisystem inflammatory syndrome in children among US persons infected with SARS-CoV-2","volume":"4","author":"Payne","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2024.01.037_b0175","doi-asserted-by":"crossref","unstructured":"Boehmer TK, Kompaniyets L, Lavery AM, Hsu J, Ko JY, Yusuf H, et al. Association Between COVID-19 and Myocarditis Using Hospital-Based Administrative Data \u2014 United States, March 2020\u2013January 2021. MMWR Morb Mortal Wkly Rep 2021;70:1228\u201332. 10.15585\/mmwr.mm7035e5.","DOI":"10.15585\/mmwr.mm7035e5"},{"key":"10.1016\/j.vaccine.2024.01.037_b0180","series-title":"Multisystem Inflammatory Syndrome in Adults (MIS-A) Case Definition and Information for Healthcare Providers","year":"2021"},{"key":"10.1016\/j.vaccine.2024.01.037_b0185","doi-asserted-by":"crossref","unstructured":"Moll K, Lufkin B, Fingar KR, Ke Zhou C, Tworkoski E, Shi C, et al. Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019\u20132020. Vaccine 2022:S0264410X22013731. 10.1016\/j.vaccine.2022.11.003.","DOI":"10.1016\/j.vaccine.2022.11.003"},{"key":"10.1016\/j.vaccine.2024.01.037_b0190","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.814198","article-title":"Factors influencing background incidence rate calculation: systematic empirical evaluation across an international network of observational databases","volume":"13","author":"Ostropolets","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.vaccine.2024.01.037_b0195","doi-asserted-by":"crossref","DOI":"10.1002\/pds.5631","article-title":"Assessing heterogeneity of electronic healthcare databases: a case study of background incidence rates of venous thromboembolism","author":"Russek","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2024.01.037_b0200","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1525-1497.2005.0150.x","article-title":"The incidence of herpes zoster in a United States administrative database","volume":"20","author":"Insinga","year":"2005","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.vaccine.2024.01.037_b0205","first-page":"373","article-title":"Unexplained lymphadenopathy in family practice. An evaluation of the probability of malignant causes and the effectiveness of physicians\u2019 workup","volume":"27","author":"Fijten","year":"1988","journal-title":"J Fam Pract"},{"key":"10.1016\/j.vaccine.2024.01.037_b0210","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1212\/WNL.0000000000001160","article-title":"Incidence of polyneuropathy in Utrecht, the Netherlands","volume":"84","author":"Visser","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.vaccine.2024.01.037_b0215","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1002\/art.41741","article-title":"The epidemiology of psoriatic arthritis over five decades: a population-based study","volume":"73","author":"Karmacharya","year":"2021","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.vaccine.2024.01.037_b0220","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11832-014-0556-5","article-title":"The epidemiology of transient synovitis in Liverpool","volume":"8","author":"Harrison","year":"2014","journal-title":"UK J Child Orthop"},{"key":"10.1016\/j.vaccine.2024.01.037_b0225","first-page":"445","article-title":"Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota","volume":"35","author":"Wilson","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.vaccine.2024.01.037_b0230","first-page":"1329","article-title":"Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963\u20131982","volume":"17","author":"Oddis","year":"1990","journal-title":"J Rheumatol"},{"key":"10.1016\/j.vaccine.2024.01.037_b0235","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1186\/1471-2334-13-463","article-title":"Herpes zoster surveillance using electronic databases in the Valencian Community (Spain)","volume":"13","author":"Morant-Talamante","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2024.01.037_b0240","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMsa0910881","article-title":"Regional variations in diagnostic practices","volume":"363","author":"Song","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.01.037_b0245","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.2217\/cer-2019-0091","article-title":"Ospemifene versus local estrogen: adherence and costs in postmenopausal dyspareunia","volume":"8","author":"Faught","year":"2019","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.vaccine.2024.01.037_b0250","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/pds.5066","article-title":"Impact of variable look-back periods on the incidence rates of chronic diseases using real world data","volume":"29","author":"Rosenlund","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24000501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24000501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:34:54Z","timestamp":1759404894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24000501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0264410X24000501"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.01.037","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Background incidence rates of health outcomes in populations at risk for Lyme disease using US administrative claims data","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.01.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Pfizer, Inc. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}